ZAMZURA
Live / Allowed — Third extension granted (statement of use) (as of 12 May 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 20 Feb 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98411925
- Mark type
- Word mark
- Filed
- 20 Feb 2024
- Published for opposition
- 08 Oct 2024
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and gene therapy products in the nature of injectable biologic preparations for genetic, neurological, motor neuron, and neuromuscular diseases, disorders and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials for treating spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparation in the nature of biological preparations containing genetic materials for sustained survival motor neuron protein expression
Owner
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
Prior registrations
Prosecution history
- 13 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 May 2026 — SOU EXTENSION 3 GRANTED
- 12 May 2026 — SOU EXTENSION 3 FILED
- 12 May 2026 — SOU TEAS EXTENSION RECEIVED
- 19 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Nov 2025 — SOU EXTENSION 2 GRANTED
- 18 Nov 2025 — SOU EXTENSION 2 FILED
- 18 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 14 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 May 2025 — SOU EXTENSION 1 GRANTED
- 13 May 2025 — SOU EXTENSION 1 FILED
- 13 May 2025 — SOU TEAS EXTENSION RECEIVED
- 19 Nov 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Oct 2024 — PUBLISHED FOR OPPOSITION